2024

2024730

PR Heartseed Announces Positive Recommendation from Safety Monitoring Committee for Dose Escalation in Phase 1/2 Clinical Trial Dosed With HS-001

2024730

PR Notice of Listing on the Growth Market of the Tokyo Stock Exchange

2024626

PR Notice of Approval for Listing on the Growth Market of the Tokyo Stock Exchange

202458

Congress Initial Results of the LAPiS Trial with HS-001 to Be Presented at the 2024 European Society of Cardiology - Heart Failure Congress

202452

PR Heartseed.'s CFO, Mutsuki Takano, Named "Most Innovative CFO from Asia to Watch in 2024" by CXO Magazine

2024430

Publication News manuscript about the "Regeneration of Nonhuman Primate Hearts With Human Induced Pluripotent Stem Cell-Derived Cardiac Spheroids" was published in Circulation.

202449

PR Prof. Massimiliano Gnecchi, Renowned Translational Cardiology Expert, Delivers Lecture at Heartseed.

2024325

PR Heartseed CEO Keiichi Fukuda Wins Japanese Society for Regenerative Medicine "Achievement Award"

202436

PR Heartseed CEO Keiichi Fukuda Delivers Keynote on Regenerative Medicine at aichung Veterans General Hospital in Taiwan

2024227

Media Heartseed was selected as the Japan's ten hottest biotech companies in healthcare by LABIOTECH

1 2